- Home
- EGY vs KRRO Comparison
EGY vs KRRO Comparison
Compare EGY & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- KRRO
- Stock Information
- Founded
- EGY 1985
- KRRO 2014
- Country
- EGY United States
- KRRO United States
- Employees
- EGY N/A
- KRRO N/A
- Industry
- EGY Oil & Gas Production
- KRRO Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- KRRO Health Care
- Exchange
- EGY Nasdaq
- KRRO Nasdaq
- Market Cap
- EGY 412.9M
- KRRO 358.3M
- IPO Year
- EGY N/A
- KRRO 2019
- Fundamental
- Price
- EGY $3.74
- KRRO $6.25
- Analyst Decision
- EGY
- KRRO Buy
- Analyst Count
- EGY 0
- KRRO 10
- Target Price
- EGY N/A
- KRRO $74.17
- AVG Volume (30 Days)
- EGY 701.9K
- KRRO 919.9K
- Earning Date
- EGY 11-10-2025
- KRRO 11-12-2025
- Dividend Yield
- EGY 6.68%
- KRRO N/A
- EPS Growth
- EGY N/A
- KRRO N/A
- EPS
- EGY 0.27
- KRRO N/A
- Revenue
- EGY $389,951,000.00
- KRRO $7,371,000.00
- Revenue This Year
- EGY N/A
- KRRO $116.91
- Revenue Next Year
- EGY $23.20
- KRRO N/A
- P/E Ratio
- EGY $13.86
- KRRO N/A
- Revenue Growth
- EGY N/A
- KRRO N/A
- 52 Week Low
- EGY $3.00
- KRRO $5.70
- 52 Week High
- EGY $5.47
- KRRO $56.69
- Technical
- Relative Strength Index (RSI)
- EGY 44.23
- KRRO 20.72
- Support Level
- EGY $3.66
- KRRO $5.70
- Resistance Level
- EGY $3.95
- KRRO $33.92
- Average True Range (ATR)
- EGY 0.12
- KRRO 3.03
- MACD
- EGY -0.01
- KRRO -3.61
- Stochastic Oscillator
- EGY 25.00
- KRRO 1.49
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.